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INTRODUCTION
• Funding of new therapies is dependent on the value perceived by payers. The process involves multi-criteria decision analysis, which considers unmet need, disease morbidity and mortality, comparative clinical benefit, patient quality of life and product safety.
• Traditionally, overall survival (OS) has been considered the "gold standard" for evaluating new oncology treatments, because death is easy to define and is not subject to investigator bias.
• Although reliable and simple to measure, this endpoint takes years to observe and is often confounded as the options for continuing therapy increase.
• However, for many oncology products, an OS benefit may not be demonstrated at product launch. This may be due to accelerated regulatory approval based on surrogate endpoints, single-arm trial design, confounding of the OS outcome due to therapy cross-over, or difficulties in demonstrating OS benefit due to tumour type and stage of treatment.
• Lack of OS data can leave payers in a dilemma regarding reimbursement. This study examines decision by the pan-Canadian Oncology Drug Review (pCODR), which was established to assess the clinical evidence and costeffectiveness of new cancer drugs and make recommendations to the provinces and territories, excluding Québec, to guide their drug funding decisions.
OBJECTIVE
• The objective of this study was to examine:
(1) what proportion of positive reimbursement recommendations by pCODR occurred despite a lack of statistically significant OS data;
(2) the proportion of negative recommendations that noted a lack of OS data as a contributing factor; and (3) factors that may have influenced a positive recommendation in the absence of statistically significant OS data.
METHODS
• Final pCODR Expert Review Committee (pERC) recommendations and Clinical Guidance Panel reports were identified from inception (13 July 2011) to 28 April 2014. Using only publicly available information (accessible at www.pcodr.ca and www.reimbursementdecisions.com), recommendations were analyzed under the following categories: submission specifics, drug characteristics, clinical factors and economic factors. Descriptive analyses were conducted to identify trends for positive and negative recommendations.
RESULTS
• The 32 submissions covered 38 indications and included 28 positive recommendations.
• Of the 10 indications that received a negative recommendation, 7 (70%) were based on RCT data while 3 (30%) were based on single-arm trial data (Figure 1) .
• Of the 28 indications that received a positive recommendation, 24 (86%) were based on RCT data while 4 (14%) were based on single-arm trial data (Figure 1 ).
-58% of the positive recommendations based on RCT data lacked statistically significant OS data.
-The pERC rationale for positive recommendations in the absence of statistically significant OS findings are summarized in 
CONCLUSIONS
• This study highlights that positive reimbursement recommendations may be made in the absence of a clear OS benefit.
• The positive pERC recommendations were influenced by unmet need, methodological limitations with obtaining statistically significant OS data and strong non-OS clinical data.
• Similar findings have been observed in recommendations by reimbursement agencies in other countries; however, more extensive research is required to fully investigate the multinational trends for reimbursement of oncology products when statistically significant OS data are lacking.
• The findings of this study are relevant to research methodologists, clinical trial designers and market access stakeholders as they provide insights into the factors that may influence reimbursement and should be considered in product development.
